Evaluation of Rapid Diagnostic Device for the Detection of Candida Auris

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

"Candida auris is an emerging fungus that can cause severe infections, particularly in hospitalized patients, and is often resistant to multiple antifungal treatments. Rapid and accurate detection of this pathogen is essential to control its spread in healthcare settings.

This study aims to evaluate the clinical performance of the NG-Test® Candida auris rapid diagnostic test (RDT), developed by CEA and NG Biotech. The test uses immunochromatography and can detect Candida auris in about 15 minutes. Its results will be compared to the reference method, MALDI-TOF, performed on colonies grown from routine patient samples.

Both retrospective (using stored isolates) and prospective (using new isolates) evaluations will be conducted. The study will measure the sensitivity and specificity of the test, and also include an assessment of its ease of use by laboratory staff. No additional samples will be collected from patients, and all testing will use de-identified isolates to ensure confidentiality."

Eligibility criteria

Qualifiers

None

Disqualifiers

NA

Trial design

Treatments tested in this trial

  • NG-TestⓇ C.auris kit

Treatment groups

No treatment groups listed

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor

NG Biotech

Collaborator

Commissariat A L'energie Atomique

Collaborator